CSL's $5 billion Vifor impairment is the acquisition hangover thesis on a slide
Plan (drafter input)
CSL cut FY26 guidance below consensus ($15.2B revenue vs. $15.8B expected, $3.1B Npata vs. $3.35B), flagged $5 billion in non-cash impairments mostly tied to the Vifor acquisition it paid $11.7B for in 2022. Cam's angle: this is the acquisition hangover thesis playing out in real time. A deal priced to synergy fantasy, impairments flowing through years later, interim CEO doing a 90-day review that surfaces what the original underwriting glossed over. The button: the synergy line in the original deck was doing a lot of work. It usually is.
CSL Vifor is a textbook Cam case — M&A priced to fantasy, now reckoning with reality. Specific numbers from the cluster make this concrete. Hero_text lets him lay out the before/after acquisition math.
special_message: Generate exactly 5 items: 1 with content_format='video' and 4 with content_format='hero_text'.
Body
CSL just cut FY26 guidance to $15.2B revenue and $3.1B Npata. Consensus was $15.8B and $3.35B. That's not a rounding error. The interim CEO runs a 90-day review and surfaces $5 billion in non-cash impairments, mostly tied to Vifor intangibles and under-used assets. Vifor, if you're keeping score, cost $11.7 billion in 2022.
This is what the acquisition hangover looks like from the inside. There are specific line items doing work here: $300 million from U.S. immunoglobulin channel inventory normalization, $200 million from China albumin market-value declines, another $150 million from Middle East conflict and iron competition. Each one of those was a risk a disciplined underwriter flags in the base case, not the synergy case. The efficiency program targeting $500–$550 million in annual savings by FY28 tells you everything about where the original model assumed the fat was.
The 90-day review is the tell. A permanent CEO signs the original deck. An interim CEO reads it cold. What they find is what the deal price was actually built on. In 2022 that synergy line in the Vifor pitch was doing a lot of work. It usually is.
Caption
CSL cut guidance and flagged $5B in impairments. The Vifor deal priced the synergy case. The 90-day review found the base case. #equities #valueinvesting #earnings #capitalallocation
Pipeline
- Hero image done fal · fal-ai/flux-pro/v1.1-ultraOIu_jQdRzTSu_hero.png$0.06api 12.7sMay 11, 3:38 PM
Chat References
No bot turns have referenced this post yet.